Contradictorily, considering anti-IL-17, it has also been described that the risk of serious infections is unchanged or low over the short term; therefore, in an acute setting of COVID-19, the benefit of anti-IL-17 might outweigh the risks of the infection [49]. This evidence concerns the gene IL17A and COVID-19.